{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:02:27Z","timestamp":1790344947075,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ero.2026.100206","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:30:59Z","timestamp":1782387059000},"page":"100206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Faecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatologic diseases: what is new in the last 5 years (2020-2025)?"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-2409","authenticated-orcid":false,"given":"Caroline","family":"Morizot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Jouzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Netter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailish","family":"Honap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Loeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ero.2026.100206_bib0001","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/BOR.0000000000000070","article-title":"Relevance of the gut\/joint axis for the management of spondyloarthritis in daily clinical practice","volume":"26","author":"Cypers","year":"2014","journal-title":"Curr Opin Rheumatol."},{"key":"10.1016\/j.ero.2026.100206_bib0002","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/1744666X.2021.1991315","article-title":"Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician","volume":"17","author":"Lubrano","year":"2021","journal-title":"Expert Rev Clin Immunol."},{"key":"10.1016\/j.ero.2026.100206_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241251600","article-title":"Biomarkers in inflammatory bowel disease: a practical guide","volume":"17","author":"Clough","year":"2024","journal-title":"Ther Adv Gastroenterol."},{"key":"10.1016\/j.ero.2026.100206_bib0004","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/ecco-jcc\/jjz205","article-title":"Faecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatological diseases: a systematic review","volume":"14","author":"Fauny","year":"2020","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.ero.2026.100206_bib0005","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.38967","article-title":"Brief report: intestinal dysbiosis in ankylosing spondylitis","volume":"67","author":"Costello","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ero.2026.100206_bib0006","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13075-017-1223-2","article-title":"A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis","volume":"19","author":"Klingberg","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.ero.2026.100206_bib0007","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10067-022-06297-7","article-title":"Implementation of screening criteria for inflammatory bowel disease in patients with spondyloarthritis and its association with disease and endoscopic activity","volume":"42","author":"Guti\u00e9rrez-S\u00e1nchez","year":"2023","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.ero.2026.100206_bib0008","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5935\/0004-2749.20230008","article-title":"Fecal calprotectin levels in acute anterior uveitis in patients with spondyloarthritis","volume":"86","author":"Gazim","year":"2023","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.ero.2026.100206_bib0009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41927-025-00478-y","article-title":"Impact of gastrointestinal and psychological symptoms on disease activity and functional impairment in patients with spondyloarthritis: a cross-sectional study","volume":"9","author":"Arzuaga-Hern\u00e1ndez","year":"2025","journal-title":"BMC Rheumatol."},{"key":"10.1016\/j.ero.2026.100206_bib0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejr.2023.10.001","article-title":"Screening of silent inflammatory bowel disease in seronegative spondyloarthritis patients: fecal calprotectin, ileo-colonoscopy and histopathology assessment","volume":"46","author":"Badran","year":"2024","journal-title":"Egypt Rheumatol."},{"key":"10.1016\/j.ero.2026.100206_bib0011","doi-asserted-by":"crossref","DOI":"10.1093\/discim\/kyae005","article-title":"Elevated type-17 cytokines are present in axial spondyloarthritis stool","volume":"3","author":"Brough","year":"2024","journal-title":"Discov Immunol."},{"key":"10.1016\/j.ero.2026.100206_bib0012","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/1756-185X.14388","article-title":"Fecal calprotectin as a biomarker of microscopic bowel inflammation in patients with spondyloarthritis","volume":"25","author":"Campos","year":"2022","journal-title":"Int J Rheum Dis."},{"key":"10.1016\/j.ero.2026.100206_bib0013","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3390\/diagnostics14222591","article-title":"Elevated calprotectin levels reveal loss of vascular pattern and atrophy of villi in ileum by digital chromoendoscopy and magnification colonoscopy in patients with spondyloarthritis without having inflammatory bowel disease","volume":"14","author":"De Avila","year":"2024","journal-title":"Diagnostics (Basel)."},{"key":"10.1016\/j.ero.2026.100206_bib0014","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.reuma.2020.10.002","article-title":"The clinical utility of faecal calprotectin in patients with differentiated and undifferentiated spondyloarthritis: relevance and clinical implications","volume":"18","author":"Emad","year":"2022","journal-title":"Reumatol Clin (Engl Ed)."},{"key":"10.1016\/j.ero.2026.100206_bib0015","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ajg.2021.05.020","article-title":"Investigation of asymptomatic intestinal inflammation in ankylosing spondylitis by fecal calprotectin","volume":"22","author":"Ercalik","year":"2021","journal-title":"Arab J Gastroenterol"},{"key":"10.1016\/j.ero.2026.100206_bib0016","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/03009742.2020.1748707","article-title":"Relationship between faecal calprotectin and inflammation in peripheral joints and entheses in axial spondyloarthritis","volume":"49","author":"Kang","year":"2020","journal-title":"Scand J Rheumatol."},{"key":"10.1016\/j.ero.2026.100206_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106948","article-title":"Calprotectin in spondyloarthritis: a systematic review and meta-analysis","volume":"88","author":"Ma","year":"2020","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.ero.2026.100206_bib0018","first-page":"203","article-title":"The role of faecal calprotectin in the evaluation of disease activity in spondyloarthritis patients: a cross-sectional study","volume":"12","author":"Sarsilmaz","year":"2024","journal-title":"Nam Kem Med J."},{"key":"10.1016\/j.ero.2026.100206_bib0019","first-page":"31","article-title":"Association of fecal calprotectin and lipocalin-2 with subclinical intestinal inflammation and disease activity in patients with axial spondyloarthritis","volume":"61","author":"Sayed","year":"2025","journal-title":"Alex J Med."},{"key":"10.1016\/j.ero.2026.100206_bib0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejr.2025.06.001","article-title":"Calprotectin in patients with axial spondyloarthritis: clinical features, disease activity and imaging","volume":"47","author":"Shedid","year":"2025","journal-title":"Egypt Rheumatol."},{"issue":"Suppl 10","key":"10.1016\/j.ero.2026.100206_bib0021","article-title":"Increased levels of F\u2011calprotectin in patients with early rheumatoid arthritis at diagnosis","volume":"76","author":"Einarsson","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ero.2026.100206_bib0022","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.3390\/nu15102386","article-title":"Assessment of intestinal permeability and inflammation bio-markers in patients with rheumatoid arthritis","volume":"15","author":"Heidt","year":"2023","journal-title":"Nutrients."},{"key":"10.1016\/j.ero.2026.100206_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1092118","article-title":"Gut-joint axis: gut dysbiosis can contribute to the onset of rheumatoid arthritis via multiple pathways","volume":"13","author":"Romero-Figueroa","year":"2023","journal-title":"Front Cell Infect Microbiol."},{"key":"10.1016\/j.ero.2026.100206_bib0024","doi-asserted-by":"crossref","first-page":"522","DOI":"10.46497\/ArchRheumatol.2024.10557","article-title":"Fecal calprotectin levels in patients with fibromyalgia: a cross-sectional study","volume":"39","author":"\u00c7\u0131nar","year":"2024","journal-title":"Arch Rheumatol."},{"key":"10.1016\/j.ero.2026.100206_bib0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13075-022-02733-w","article-title":"Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis","volume":"24","author":"Sagard","year":"2022","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.ero.2026.100206_bib0026","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ero.2026.100206_bib0027","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/apt.15397","article-title":"Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents","volume":"50","author":"Yamada","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.ero.2026.100206_bib0028","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ero.2026.100206_bib0029","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/apt.70139","article-title":"Risk of de novo inflammatory bowel disease in patients with psoriasis and psoriatic arthritis treated with IL-17A inhibitors: a population-based study","volume":"62","author":"Alsakarneh","year":"2025","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.ero.2026.100206_bib0030","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2023.11.304","article-title":"Dysbiosis and associated stool features improve prediction of response to biological therapy in inflammatory bowel disease","volume":"166","author":"Caenepeel","year":"2024","journal-title":"Gastroenterology."},{"key":"10.1016\/j.ero.2026.100206_bib0031","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v32.i6.115941","article-title":"Long-term clinical outcomes with filgotinib in ulcerative colitis: 12-month results from the FILGUITO study","volume":"32","author":"Caballero-Mateos","year":"2026","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.ero.2026.100206_bib0032","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn\u2019s disease. The North American Crohn\u2019s Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ero.2026.100206_bib0033","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/clinchem\/hvad051","article-title":"Fecal calprotectin in gastrointestinal disease","volume":"69","author":"Murray","year":"2023","journal-title":"Clin Chem"},{"key":"10.1016\/j.ero.2026.100206_bib0034","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.3748\/wjg.v24.i33.3681","article-title":"From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting","volume":"24","author":"Mumolo","year":"2018","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.ero.2026.100206_bib0035","first-page":"21","article-title":"Fecal calprotectin in inflammatory bowel disease","volume":"9","author":"Walsham","year":"2016","journal-title":"Clin Exp Gastroenterol."},{"key":"10.1016\/j.ero.2026.100206_bib0036","first-page":"53","article-title":"The use of fecal calprotectin in inflammatory bowel disease","volume":"13","author":"Bjarnason","year":"2017","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.ero.2026.100206_bib0037","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3892\/br.2016.751","article-title":"Calprotectin as a diagnostic tool for inflammatory bowel diseases (review)","volume":"5","author":"Chatzikonstantinou","year":"2016","journal-title":"Biomed Rep."}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126001059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126001059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:30:50Z","timestamp":1790343050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708126001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3050708126001059"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2026.100206","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Faecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatologic diseases: what is new in the last 5 years (2020-2025)?","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2026.100206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}],"article-number":"100206"}}